Opportunities in South America and Europe make Mexico's pharma industry uniquely placed

8 July 2019

Mexico’s pharmaceutical industry – renowned for the quality and reliability of its medicines production – sees South America and Europe as its main export markets.

By value, Mexico comes 27th in a list of the top medicines exporting countries globally, with around $1.2 billion – the highest in Latin America – and by volume it comes much higher.

The fact that markets as large as South America, followed by Europe, provide the most significant export regions for Mexico, mean that new opportunities abound for new alliances and growth, said Efren Hernandez, president of the Mexican Pharmaceutical Association, speaking to The Pharma Letter's local correspondent.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK